Skip to main content

Belite Bio, Inc (BLTE) Stock Forecast

Data as of Aug 5, 2026

Healthcare · Current price $157.40 (+1.69%)

Consensus Target
$208.00
Upside
+32.9%
Analysts
8
Rating
Buy(2.00)

Price Target Range

Low $191.00Consensus $208.00High $217.00
▲ Current $157.40

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy3
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

BLTE vs Sector & Market

MetricBLTEHealthcare AvgLarge Cap Avg
Analyst Rating2.002.252.42
Analyst Count8818
Target Upside+32.9%+16316.1%+17.1%
P/E Ratio-68.593.3936.31

Revenue Estimates

PeriodLowAvgHigh#
2027-03-31$16M$16M$16M1
2027-06-30$32M$32M$32M1
2027-09-30$47M$47M$47M1
2027-12-31$63M$63M$63M1
2028-03-31$86M$86M$86M1
2028-06-30$90M$90M$90M1
2028-09-30$98M$98M$98M1
2028-12-31$101M$101M$101M1

EPS Estimates

PeriodLowAvgHigh#
2027-03-31$-0.41$-0.41$-0.411
2027-06-30$-0.13$-0.13$-0.131
2027-09-30$0.09$0.09$0.091
2027-12-31$0.36$0.36$0.361
2028-03-31$0.00$0.00$0.002
2028-06-30$0.00$0.00$0.002
2028-09-30$0.00$0.00$0.002
2028-12-31$0.00$0.00$0.002

Frequently Asked Questions

What is the analyst consensus for BLTE?

The consensus among 8 analysts covering Belite Bio, Inc (BLTE) is Buy with an average price target of $208.00.

What is the highest price target for BLTE?

The highest analyst price target for BLTE is $217.00.

What is the lowest price target for BLTE?

The lowest analyst price target for BLTE is $191.00.

How many analysts cover BLTE?

8 analysts have issued ratings for Belite Bio, Inc in the past 12 months.

Is BLTE a buy or sell right now?

Based on 8 analyst ratings, BLTE has a consensus rating of Buy (2.00/5) with a +32.9% upside to the consensus target of $208.00.

What are the earnings estimates for BLTE?

Analysts estimate BLTE will report EPS of $-0.41 for the period ending 2027-03-31, with revenue estimated at $16M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.